Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 5, 2016, Pages 611-616

  Mavrogeni, Sophie I ^a   Sfikakis, Petros P ^b   Kitas, George D ^c   Kolovou, Genovefa ^a   Tektonidou, Maria G ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Cardiovascular magnetic resonance imaging; Computed tomography; Echocardiography; Nuclear cardiology

Indexed keywords

GADOLINIUM;

ANTIPHOSPHOLIPID SYNDROME; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSESSMENT; DISEASE SEVERITY; HEART ATRIUM THROMBOSIS; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART VENTRICLE FUNCTION; HUMAN; LUNG EMBOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIOLOGICAL PROCEDURES; REVIEW; SYNDROME X; SYSTEMATIC REVIEW (TOPIC); TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; COMPLICATION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

ANTIPHOSPHOLIPID SYNDROME; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

EID: 84961619732     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.09.005     Document Type: Review

References (72)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
3. Amigo M.C. The heart and APS. Clin Rev Allergy Immunol 2007, 32:178-183.
4. Tenedios F., Erkan D., Lockshin M.D. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005, 14:691-696.
5. Silbiger J.J. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr 2009, 22:1100-1108.
6. Erdozain J.G., Ruiz-Irastorza G., Segura M.I., Amigo M.C., Espinosa G., Pomar J.L., et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res 2012, 64:1256-1260.
7. Hojnik M., George J., Ziporen L., Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996, 93:1579-1587.
8. Moyssakis I., Tektonidou M.G., Vasilliou V.A., Samarkos M., Votteas V., Moutsopoulos H.M. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007, 120:636-642.
9. Tektonidou M.G., Ioannidis J.P., Moyssakis I, Boki K.A., Vassiliou V., Vlachoyiannopoulos P.G. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis 2001, 60:43-48.
10. Pardos-Gea J., Avegliano G., Evangelista A., Vilardell M., Ordi-Ros J. Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis 2015, 18:76-83.
11. Kampolis C., Tektonidou M., Moyssakis I., Tzelepis G.E., Moutsopoulos H., Vlachoyiannopoulos P.G. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum 2014, 43:558-565.
12. Abanador-Kamper N., Wolfertz J., Kamper L., Haage P., Seyfarth M. Disseminated intracardiac thrombosis: a rare manifestation of antiphospholipid syndrome. Eur Heart J Cardiovasc Imaging 2012, 13:537.
13. Mottram P.M., Gelman J.S. Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J Am Soc Echocardiogr 2002, 15:746-748.
14. Zuily S., Wahl D. Pulmonary hypertension in antiphospholipid syndrome. Curr Rheumatol Rep 2015, 17:47.
15. Andreoli L., Chighizola C.B., Banzato A., Pons-Estel G.J., Ramire de Jesus G., Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 2013, 65:1869-1873.
16. Yedlapati N., Paladugu N., Spevack D.M. Prinzmetal's angina in patients with antiphospholipid syndrome. Coron Artery Dis 2011, 22:537-539.
17. Sangle S.R., D'Cruz D.P. Syndrome X (angina pectoris with normal coronary arteries) and myocardial infarction in patients with anti-phospholipid (Hughes) syndrome. Lupus 2008, 17:83-85.
18. Onea R., Germain P., Zimmermann A. Coronary microvasculopathy and intracardiac thrombosis in antiphospholipid syndrome. Arch Cardiovasc Dis 2012, 105:461-462.
19. Kattwinkel N., Villanueva A.G., Labib S.B., Aretz H.T., Walek J.W., Burns D.L., et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992, 116:974-976.
20. Azeem T., Vassallo M., Samani N.J. Images in cardiology. Endomyocardial fibrosis associated with antiphospholipid syndrome. Heart 2000, 84:156.
21. Zavaleta N.E., Montes R.M., Soto M.E., Vanzzini N.A., Amigo M.C. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 2004, 31:2402-2407.
22. Abreu M.M., Danowski A., Wahl D.G., Amigo M.C., Tektonidou M., Pacheco M.S., et al. The relevance of non-criteria clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015, 14:401-414.
23. Plastiras S.C., Pamboucas C.A., Tektonidou M., Toumanidis S.T. Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. Eur J Echocardiogr 2010, 11:184-185.
24. Turiel M., Sarzi-Puttini P., Peretti R., Bonizzato S., Muzzupappa S., Atzeni F., et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005, 96:574-579.
25. Aguilar J.A., Summerson C. Intracardiac thrombus in antiphospholipid antibody syndrome. J Am Soc Echocardiogr 2000, 13:873-875.
26. Visser C.A., Kan G., David G.K., Lie K.I., Durrer D. Two dimensional echocardio-graphy in the diagnosis of left ventricular thrombus. A prospective study of 67 patients with anatomic validation. Chest 1983, 83:228-232.
27. Stratton J.R., Lighty G.W., Pearlman A.S., Ritchie J.L. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation 1982, 66:156-166.
28. Starling M.R., Crawford M.H., Sorensen G.S., Grover F.L. Comparative value of invasive and noninvasive techniques for identifying left ventricular mural thrombi. Am Heart J 1983, 106:1143-1149.
29. Schweizer P., Bardos P., Erbel R. Detection of left atrial thrombi by echocardio-graphy. Br Heart J 1981, 45:148-156.
30. Shrestha N.K., Moreno F.L., Narciso F.V., Torres L., Calleja H.B. Two-dimensional echocardiographic diagnosis of left-atrial thrombus in rheumatic heart disease. A clinicopathological study. Circulation 1983, 67:341-347.
31. DePace N.L., Soulen R.L., Kotler M.N., Mintz G.S. Two dimensional echocardio-graphic detection of intraatrial masses. Am J Cardiol 1981, 48:954-960.
32. Daniel W.G., Mugge A. Transesophageal echocardiography. N Engl J Med 1995, 332:1268-1278.
33. Manning W.J., Weintraub R.M., Waksmonski C.A., Haering J.M., Rooney P.S., Maslow A.D., et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995, 123:187-822.
34. Espinola-Zavaleta N., Alexanderson-Rosas E., Granados N., Elena Soto M., Amigo M.C. Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests. Lupus 2006, 15:38-43.
35. Vlachoyiannopoulos P.G., Kanellopoulos P.G., Ioannidis J.P., Tektonidou M.G., Mastorakou I., Moutsopoulos H.M. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 2003, 42:645-651.
36. Schmidt W.A., Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005, 17:9-15.
37. Bleiweis M.S., Georgiou D., Brundage B.H. Detection of intracardiac masses by ultrafast computed tomography. Am J Card Imaging 1994, 8:63-68.
38. Hur J., Pak H.N., Kim Y.J., Lee H.J., Chang H.J., Hong Y.J., et al. Dual-enhancement cardiac computed tomography for assessing left atrial thrombus and pulmonary veins before radiofrequency catheter ablation for atrial fibrillation. Am J Cardiol 2013, 112:238-244.
39. Provenzale J.M., Ortel T.L. Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings. Am J Roentgenol 1995, 165:365-368.
40. Shelbert H.R. Principles of positron emission tomography. Cardiac imaging 1991, 1140-1270. WB Saunders, Philadelphia. M.L. Marcus, H.R. Shelbert, D.J. Skorton, G.L. Wolf (Eds.).
41. Alexánderson E., Gómez-León A., Vargas A., Romero J.L., Sierra Fernández C., Rodriguez Valero M., et al. Myocardial ischaemia in patients with primary APS: a 13N-ammonia PET assessment. Rheumatology 2008, 47:894-896.
42. Alexanderson E., Cruz P., Vargas A., Meave A., Ricalde A., Talayero J.A., et al. Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography. J Nucl Cardiol 2007, 14:566-572.
43. Dimitroulas T., Mavrogeni S., Kitas G.D. Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. Nat Rev Rheumatol 2012, 8:203-213.
44. Mavrogeni S., Bratis K., van Wijk K., Stavropoulos E., Hautemann D., Reiber J.H., et al. Myocardial perfusion-fibrosis pattern in systemic sclerosis, assessed by cardiac magnetic resonance. Int J Cardiol 2012, 159:e56-e58.
45. Panting J.R., Gatehouse P.D., Yang G.Z., Grothues F., Firmin D.N., Collins P., et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002, 346:1948-1953.
46. Schwitter J., Nanz D., Kneifel S., Bertschinger K., Buchi M., Knusel P.R., et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation 2001, 103:2230-2235.
47. Bernhardt P., Levenson B., Albrecht A., Engels T., Strohm O. Detection of cardiac small vessel disease by adenosine-stress magnetic resonance. J Cardiol 2007, 121:261-266.
48. Greenwood J.P., Maredia N., Younger J.F., Brown J.M., Nixon J., Everett C.C., et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012, 379:453-460.
49. Kim R.J., Chen E.L., Lima J.A., Judd R.M. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996, 94:3318-3326.
50. Kim R.J., Wu E., Rafael A., Chen E.L., Parker M.A., Simonetti O., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
51. Judd R.M., Lugo-Olivieri C.H., Arai M., Kondo T., Croisille P., Lima J.A., et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation 1995, 92:1902-1910.
52. Kim R.J., Fieno D.S., Parrish T.B., Harris K., Chen E.L., Simonetti O., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
53. Fieno D.S., Kim R.J., Chen E.L., Lomasney J.W., Klocke F.J., Judd R.M. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000, 36:1985-1991.
54. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001, 357:21-28.
55. Kaandorp T.A., Lamb H.J., Poldermans D., Viergever E.P., Boersma E., van der Wall E.E., et al. Assessment of right ventricular infarction with contrast-enhanced magnetic resonance imaging. Coron Artery Dis 2007, 18:39-43.
56. Kumar A., Abdel-Aty H., Kriedemann I., Schulz-Menger J., Gross C.M., Dietz R., et al. Contrast enhanced cardiovascular magnetic resonance imaging of right ventricular infarction. J Am Coll Cardiol 2006, 48:1969-1976.
57. Larose E., Ganz P., Reynolds H.G., Dorbala S., Di Carli M.F., Brown K.A., et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol 2007, 49:855-862.
58. Roes S.D., Kelle S., Kaandorp T.A., Kokocinski T., Poldermans D., Lamb H.J., et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002, 105:162-167.
59. Wagner A., Mahrholdt H., Holly T.A., Elliott M.D., Regenfus M., Parker M., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003, 361:374-379.
60. Bondarenko O., Beek A.M., Nijveldt R., McCann G.P., van Dockum W.G., Hofman M.B., et al. Functional outcome after revascularization in patients with chronic ischemic heart disease: a quantitative late gadolinium enhancement CMR study evaluating transmural scar extent, wall thickness and periprocedural necrosis. J Cardiovasc Magn Reson 2007, 9:815-821.
61. Mavrogeni S., Kouranos V., Sfikakis P.P., Bratis K., Kitas G.D., Manali E., et al. Myocardial stress perfusion-fibrosis imaging pattern in sarcoidosis, assessed by cardiovascular magnetic resonance imaging. Int J Cardiol 2014, 172:501-503.
62. Ishimori M.L., Martin R., Berman D.S., Goykhman P., Shaw L.J., Shufelt C., et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging 2011, 4:27-33.
63. Mavrogeni S., Sfikakis P.P., Karabela G., Stavropoulos E., Spiliotis G., Gialafos E., et al. Cardiovascular magnetic resonance imaging in asymptomatic patients with connective tissue disease and recent onset left bundle branch block. Int J Cardiol 2014, 171:82-87.
64. Mavrogeni S., Sfikakis P.P., Gialafos E., Bratis K., Karabela G., Stavropoulos E., et al. Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res 2014, 66:104-112.
65. Sacré K., Brihaye B., Hyafil F., Serfaty J.M., Escoubet B., Zennaro M.C., et al. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010, 62:2093-2100.
66. Cury R.C., Abbara S., Sandoval L.J., Houser S., Brady T.J., Palacios I.F. Images in cardiovascular medicine. Visualization of endomyocardial fibrosis by delayed-enhancement magnetic resonance imaging. Circulation 2005, 111:e115-e116.
67. Gonçalves L.F., Souto F.M., Faro F.N., Oliveira J.L., Barreto-Filho J.A., Sousa A.C. Biventricular thrombus and endomyocardial fibrosis in antiphospholipid syndrome. Arq Bras Cardiol 2012, 99:e162-e165.
68. Varghese A., Pennell D. Cardiovascular magnetic resonance made easy 2008, 16-19. Elsevier, Churchill Livingstone.
69. Barkhausen J., Hunold P., Eggebrecht H., Schüler W.O., Sabin G.V., Erbel R., et al. Detection and characterization of intracardiac thrombi on MR imaging. Am J Roentgenol 2002, 179:1539-1544.
70. Weinsaft J.W., Kim R.J., Ross M., Krauser D., Manoushagian S., LaBounty T.M., et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009, 2:969-979.
71. Srichai M.B., Junor C., Rodriguez L.L., Stillman A.E., Grimm R.A., Lieber M.L., et al. Clinical, imaging, and pathological chara-cteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardio-graphy with surgical or pathological validation. Am Heart J 2006, 152:75-84.
72. Quarta G., Holdright D.R., Plant G.T., Harkness A., Hausenloy D., Hyare H., et al. Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ. J Cardiovasc Magn Reson 2011, 13:26.